central and peripheral glp-1 systems independently suppress eating The GLP-1: implications for food drug reward Neurobiological Mechanisms and Therapeutic Potential

Current Clinical Pharmacology, 12 (4), 253258

While GLP-1RA continue to be successful 17 , combinatorial approaches are being developed due to the hypothesis that additional pathway engagement will generate greater weight loss, durability of weight loss and improved tolerability 7

The analysis also linked GLP-1RA use with lower risks of lower extremity amputation, revascularization, gangrene, major adverse cardiovascular events, and all-cause mortality

Although a GLP-1R agonist does not alter alcohol intake in AUD patients, it reduces this consumption in a sub-population of obese AUD individuals

The Phase 3 trial for obesity and related conditions initiated in 2025